Pune Magazine

Community-acquired Bacterial Pneumonia Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical

 Breaking News
  • No posts were found

Community-acquired Bacterial Pneumonia Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies – Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical

November 14
23:53 2022
Community-acquired Bacterial Pneumonia Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical
The dynamics of the Community-acquired Bacterial Pneumonia market are anticipated to change in the coming years owing to the launch of upcoming therapies along with the rise in the number of cases and healthcare spending across the world.

DelveInsight’s Community-acquired Bacterial Pneumonia Market Insights report includes a comprehensive understanding of current treatment practices, Community-acquired Bacterial Pneumonia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

 

Key Takeaways from the Community-acquired Bacterial Pneumonia Market

  • As per DelveInsight’s estimates, the Community-acquired Bacterial Pneumonia market size is expected to reach USD 2,866 million by 2032.
  • As per DelveInsight’s estimates, the total CABP incident cases is expected to be approx 6.9 million cases in the 7MM, which is further anticipated to increase by 2032.
  • Key Community-acquired Bacterial Pneumonia companies including Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc, Combioxin SA, Takeda, and others are having approved products for the treatment of patients affected with CABP and some of them are currently working to improve the treatment paradigm of CABP.
  • The Community-acquired Bacterial Pneumonia therapies in the pipeline include CAL02, Cx611, and others.
  • The key driver for the surge in Community-Acquired Bacterial Pneumonia market size is the rise in the number of incident cases in the 7MM.

 

Discover more about therapies set to grab major Community-acquired Bacterial Pneumonia market share @ Community-acquired Bacterial Pneumonia Market Landscape

 

Community-acquired Bacterial Pneumonia Overview

Community-acquired Bacterial Pneumonia (CABP) is a common, severe infection of the lung parenchyma. It is a leading cause of death in adults. It is one of the most common respiratory diseases among the various infections that cause sepsis. Community-acquired Bacterial Pneumonia most commonly caused by Streptococcus pneumoniae in adults worldwide. Haemophilus influenzae and Mycoplasma pneumoniae are two other common bacteria that cause Community-acquired Pneumonia (CAP). Chlamydia and mycoplasma pneumonia is frequently clinically indistinguishable from other types of pneumonia.

The CABP symptoms include malaise, chills, rigor, fever, cough, dyspnea, and chest pain. Coughing is usually productive in older children and adults but dry in infants, young children, and the elderly. Dyspnea is usually mild and exertional, and it is almost never present at rest.

 

Community-acquired Bacterial Pneumonia Epidemiology Segmentation

  • As per DelveInsight analysis, the total incident cases of CABP infection were approx 6.9 million cases in the 7MM which are anticipated to be increased by 2032.
  • Among EU5 countries, Germany had the highest number of CABP incident cases in 2019.

 

The Community-acquired Bacterial Pneumonia Market Report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

  • Incident Cases of CABP
  • Incident Cases of CABP based on Gender
  • Incident Cases of CABP based on Severity
  • Incident Cases of CABP based on Pathogens
  • Incident Cases of CABP based on Age

 

Download report to understand which factors are driving CABP infection epidemiology trends @ Community-acquired Bacterial Pneumonia Epidemiological Insights

 

Community-acquired Bacterial Pneumonia Market

Although the majority of patients with Community-acquired Pneumonia are treated empirically, but the best treatment option remains unknown. The antibiotics govern the Community-Acquired Bacterial Pneumonia treatment landscape. Nuzyra (omadacycline), Baxdela (delafloxacin), and Xenleta (lefamulin) are some of the drugs approved for the Community-Acquired Bacterial Pneumonia treatment. In addition, Recarbrio (Cilastatin/imipenem/relebactam), Fetroja (cefiderocol), Avycaz (ceftazidime-avibactam), Vibativ (telavancin), and Zerbaxa (ceftolozane + tazobactam) are among the drugs approved for hospital-acquired/ventilator-associated bacterial pneumonia (HABP). 

Moreover, in individuals 18 years of age and older, a vaccine such as Vaxneuvance is recommended for active immunization to prevent invasive disease and pneumonia caused by Streptococcus pneumoniae.

Furthermore, Community-acquired Pneumonia treatment has become difficult due to changing safety profiles and efficacy of well-established antibiotics, as well as a lack of new therapeutic options.

 

Discover more about therapy set to grab substantial Community-acquired Bacterial Pneumonia market share @ Community-acquired Bacterial Pneumonia Treatment 

 

Community-acquired Bacterial Pneumonia Pipeline Therapies and Key Players

  • CAL02: Eagle Pharmaceutical Inc/Combioxin SA
  • Cx611: Takeda

 

Scope of the Community-acquired Bacterial Pneumonia Market Report

  • Study Period: 2019-2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Community-acquired Pneumonia Companies: Nabriva Therapeutics, Melinta Therapeutics, Wakunaga Pharmaceutical, Forest Pharmaceuticals, Pfizer, Paratek Pharmaceuticals, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Merck Sharp & Dohme Inc., Cubist Pharmaceuticals LLC, Shionogi Inc., Allergan, Eagle Pharmaceutical Inc, Combioxin SA, Takeda, and others
  • Key Community-acquired Bacterial Pneumonia Pipeline Therapies: CAL02, Cx611, and others
  • Community-acquired Bacterial Pneumonia Therapeutic Assessment: Community-acquired Pneumonia current marketed and emerging therapies
  • Community-acquired Bacterial Pneumonia Market Dynamics: Community-acquired Bacterial Pneumonia market drivers and barriers
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Community-acquired Bacterial Pneumonia Unmet Needs, KOL’s views, Analyst’s views, Community-acquired Bacterial Pneumonia Market Access and Reimbursement

 

Table of Contents 

1.

Key Insights

2.

Report Introduction

3.

Community-acquired Bacterial Pneumonia Market Overview at a Glance

4.

Executive Summary

5.

Disease Background and Overview

6.

Treatment and Management

7.

Epidemiology and Patient Population

8.

Patient Journey

9.

Community-acquired Bacterial Pneumonia Marketed Therapies

10.

Emerging Drugs

11.

Other Therapies: Generics

12.

7 Major Market Analysis

13.

Community-acquired Bacterial Pneumonia Market Outlook

14.

KOL Views

15.

Unmet Needs

16.

SWOT Analysis

17.

Appendix

18.

DelveInsight Capabilities

19.

Disclaimer

20.

About DelveInsight

 

Discover more about the future Community-acquired Bacterial Pneumonia market share of treatment therapies @ Community-acquired Bacterial Pneumonia Treatment Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting

Categories